LTRN — Lantern Pharma Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1763950 ·
Last close
$2.63
Market Cap
$33.56M
52W High
$4.34
52W Low
$1.96
ADV30
141,727
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,405,247 | -3,329,171 | 7,223,067 | 4,917,796 | 3,777,366 |
| Dec 2025 | 0 | — | -4,202,762 | -4,074,217 | 11,035,811 | 4,422,838 | 4,501,587 |
| Sep 2025 | 0 | — | -4,349,800 | -4,177,423 | 13,626,810 | 8,389,486 | 4,039,972 |
| Jun 2025 | 0 | — | -4,651,900 | -4,331,015 | 17,420,292 | 6,061,408 | 4,897,887 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,073,997
Investing CF
$12,067,742
Financing CF
$1,498,240
CapEx
$-4,798
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.51
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,474,226
Inventory
—
Receivables
—
ST Investments
$1,405,057
EBIT TTM
$-16,609,709
Pretax Income TTM
$-15,911,826
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -17,978,494 | -17,119,438 | 11,035,811 | 4,501,587 | — | -15,676,980 |
| Dec 2024 | 0 | -22,216,437 | -20,781,213 | 25,571,792 | 4,384,018 | — | -17,813,201 |
| Dec 2023 | 0 | -17,877,570 | -15,961,534 | 43,647,616 | 2,739,682 | — | -14,346,548 |
| Dec 2022 | 0 | -14,432,753 | -14,259,946 | 58,836,321 | 2,798,297 | — | -12,767,492 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.02
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BETRF | BetterLife Pharma Inc. | $33.75M | $0.21 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $33.28M | $0.79 | — |
| GRCE | Grace Therapeutics, Inc. | $33.85M | $2.08 | — |
| LITS | Lite Strategy, Inc. | $32.66M | $0.96 | — |
| IXHL | Incannex Healthcare Inc. | $35.18M | $2.94 | — |
News headlines (Yahoo Finance, 1h cache)
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
2026-07-28 11:45 · Yahoo
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
2026-07-23 12:01 · Yahoo
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
2026-07-08 11:30 · Yahoo
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript
2026-05-21 14:39 · Yahoo
CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers
2026-04-24 13:25 · Yahoo
Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers
2026-04-24 13:00 · Yahoo
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
2026-04-25 16:55 · Yahoo
Promising Penny Stocks To Consider In May 2026
2026-05-15 12:05 · Yahoo
12 Health Care Stocks Moving In Wednesday's Intraday Session
2026-05-13 17:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.